GlassScriptPhysician profile
Corley Catherine Dees
NPI 1588292841
$4,433.16
in general payments reported to CMS, 2019-2025
21 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.18 · 2023: $1,833 · 2024: $2,259 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,182 · Education: $18.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,181.75 |
| Education | $18.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.01 | 2022-2024 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $529.77 | 2023-2024 | Sotyktu |
| Abbvie INC. | $307.01 | 2023-2025 | |
| Amgen INC. | $294.80 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $291.75 | 2023-2025 | |
| Incyte Corporation | $265.24 | 2023-2024 | Opzelura |
| Lilly USA, LLC | $251.65 | 2024 | Olumiant, Taltz |
| Arcutis Biotherapeutics, INC. | $245.88 | 2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $239.29 | 2024 | |
| Ucb, INC. | $219.64 | 2023-2024 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $158.04 | 2023-2024 | Dupixent |
| Galderma Laboratories, L.P. | $147.72 | 2023 | Oracea, Aklief, Twyneo |
| Sun Pharmaceutical Industries INC. | $146.39 | 2023-2024 | Ilumya, Blu-U, Odomzo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $143.33 | 2024 | Cabtreo, Siliq, Arazlo |
| Regeneron Pharmaceuticals, INC. | $130.46 | 2024 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $110.78 | 2024 | Adbry |
| Biofrontera INC. | $108.10 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Almirall LLC | $33.47 | 2023 | Seysara, Klisyri |
| Kyowa Kirin, INC. | $21.68 | 2024 | Poteligeo |
| Genentech USA, INC. | $16.14 | 2024 | Xolair |
| Janssen Biotech, INC. | $14.96 | 2025 | Stelara, Simponi Aria, Simponi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corley Dees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.